louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06680583: Utilizing of Physiological Parameters Predict the Prognosis of Cirrhotic Patients With Gastrointestinal Bleeding
Official title: Utilizing of Physiological Parameters And Derived Indices to Predict The Prognosis of Cirrhotic Patients With Gastrointestinal Bleeding
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Liver Cirrhosis
Gastrointestinal Bleeding
Keywords: cirrhosis
gastrointestinal bleeding
physical indicator
shock index
Lead sponsor: St. Martin De Porress Hospital
Sponsor class: OTHER
First posted: 2024-11-08
Enrollment: 150
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: cirrhosis with gastrointestinal bleeding

Brief summary: Can physiological indicators such as quick Sequential Organ Failure Assessment , Shock Index, and its derived indicators such as Modified Shock Index , Age Shock Index and Respiratory Adjusted Shock Index accurately predict the prognosis of cirrhosis patients with gastrointestinal bleeding? To explore the improvement of emergency and critical care patient management.

Detailed description: Cirrhosis is a common chronic liver disease with gastrointestinal bleeding being one of its complications. Gastrointestinal bleeding is quite common in patients with cirrhosis, but its prognosis is difficult to accurately predict. In current clinical practice, critical care physicians often use physiological indicators to assess the risk level of patients. Among them, the Shock Index and its derived indicators such as the Modified Shock Index, Age Shock Index, and Respiratory Adjusted Shock Index have been widely used in other fields, but their actual value in patients with cirrhosis complicated by gastrointestinal bleeding is not yet clear.

The prognosis of cirrhosis patients with gastrointestinal bleeding affects the quality of life and survival of the patients, thus necessitating the establishment of a reliable prognostic assessment tool to assist critical care physicians in making rapid treatment decisions. The motivation of this study is to explore the application value of Shock Index-related indicators in predicting the prognosis of cirrhosis patients with gastrointestinal bleeding, in order to improve the medical efficiency for this specific group of critically ill patients.

Eligibility criteria: Inclusion Criteria: cirrhosis with gastrointestinal bleeding -

Exclusion Criteria: no complete medical record and trauma patient

-

Primary outcomes:
measure: shock index= heart rate / systolic blood pressure normal range:0.5-0.7 Modified shock index = heart rate/mean arterial pressure(MAP) age shock index = SI x age number respiratory adjusted shock index(RASI) = HR/SBP × RR/10. MAP = DP + 1/3(SP - DP)
timeFrame: through study completion, an average of 6 months
Secondary outcomes:
Other outcomes:
Locations:
city: Tainan
country: Taiwan
facility: St. Martin De Porres Hospital
Study officials:
affiliation: St. Martin De Porres Hospital Education and Research
name: Yeong-Chin Jou Jou, professor
role: STUDY_DIRECTOR
References:
Clinical trial NCT04249583: Treatment of Moderate to Severe Glabellar Lines
Official title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of QM1114-DP for the Treatment of Moderate to Severe Glabellar Lines
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Glabellar Frown Lines
Lead sponsor: Galderma R&D
Sponsor class: INDUSTRY
First posted: 2020-01-31
Enrollment: 300
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The objective of the study is to evaluate the efficacy and safety of a single dose of QM1114-DP compared to placebo for the treatment of moderate to severe GL.


Eligibility criteria: Inclusion Criteria:

1. Male or female 18 years of age or older.
2. Moderate to severe GL at maximum frown as assessed by the Investigator.
3. Moderate to severe GL at maximum frown as assessed by the subject.

Exclusion Criteria:

1. Previous use of any Botulinum toxin in facial areas within 9 months prior to study treatment.
2. Female who is pregnant, breast feeding, or intends to conceive a child during the study.
3. Known allergy or hypersensitivity to any component of the investigational product (QM1114-DP) or any botulinum toxin serotype.

Primary outcomes:
measure: Percentage of Subjects With a ≥ 2-grade Improvement From Baseline on the Glabellar Lines Investigator and Subject Assessments at Maximum Frown at One Month.
timeFrame: One Month
Secondary outcomes:
measure: Percentage of Subjects With a 0 or 1 on the Glabellar Lines Investigator Scale at Maximum Frown
timeFrame: One Month
Other outcomes:
Locations:
city: Manhattan Beach
country: United States
facility: \Ablon Skin Institute and Research Center
state: California
city: Vista
country: United States
facility: Moradi MD
state: California
city: New Orleans
country: United States
facility: Etre Cosmetic Dermatology and Laser Center
state: Louisiana
city: Hunt Valley
country: United States
facility: Maryland Dermatology, Laser Skin & Vein
state: Maryland
city: Omaha
country: United States
facility: Skin Specialist, PC
state: Nebraska
city: New York
country: United States
facility: Robert Schwarcz, MD, PC
state: New York
city: New York
country: United States
facility: Sachin M Shridharani, MD
state: New York
city: Wilmington
country: United States
facility: Wilmington Dermatology Center, PLLC
state: North Carolina
city: Nashville
country: United States
facility: The Practice of Brian S Biesman, MD
state: Tennessee
city: Nashville
country: United States
facility: Tennessee Clinical Research Center
state: Tennessee
city: Dallas
country: United States
facility: Dallas Center for Dermatology & Aesthetics
state: Texas
city: Pflugerville
country: United States
facility: Austin Institute for Clinical Research, Inc.
state: Texas
city: Spring
country: United States
facility: Integrated Aesthetics, Inc
state: Texas
city: Toronto
country: Canada
facility: Sweat Clinics of Canada
state: Ontario
Study officials:
References:
Clinical trial NCT05634083: Does Indoxyl Sulfate Have a Role in Uremic Pruritus?
Official title: Does Indoxyl Sulfate Have a Role in Uremic Pruritus? A Laboratory and Interventional Study.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Pruritus
Lead sponsor: Benha University
Sponsor class: OTHER
First posted: 2022-12-01
Enrollment: 45
Sex: ALL
Minimum age (years): 18
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: Patients will take activated charcoal for two months
Primary purpose: TREATMENT

Brief summary: Itching is a widespread and disturbing complain from patients with chronic kidney disease (CKD); epidemiologic data have suggested that approximately 40% of patients with end-stage renal disease experience moderate to severe itching. The pathogenesis of renal pruritus is multifactorial. Triggering factors may include uremia-related abnormalities, accumulation of uremic toxins, systemic inflammation and cutaneous xerosis. Indoxyl sulfate (IS) is a protein-bound uremic toxin resulting from the metabolism of dietary tryptophan accumulating in patients with end-stage renal disease.

Detailed description: Patients with end-stage renal disease undergoing hemodialysis complaining of itching not related to other cause than renal failure will take activated charcoal with foods and serum level of indoxyl sulphate will be studied

Eligibility criteria: Inclusion Criteria:

Patients with end-stage renal failure with itching undergoing regular hemodialysis

Exclusion Criteria:

Patients with other causes of itching as psoriasis, atopic dermatitis, scabies, and lichen planus

Primary outcomes:
measure: Severity of itching
timeFrame: Two months
Secondary outcomes:
Other outcomes:
Locations:
city: Al Qalyūbīyah
country: Egypt
facility: Faculty of Medicine, Benha University
state: Benha
city: Banhā
country: Egypt
facility: Benha University Hospitals
Study officials:
References:
Clinical trial NCT01739283: GIP and GLP-1 in Type 1 Diabetes
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Hypoglycemia
Lead sponsor: University Hospital, Gentofte, Copenhagen
Sponsor class: OTHER
Collaborators: name: University of Copenhagen
First posted: 2012-12-03
Enrollment: 10
Sex: MALE
Minimum age (years): 18
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: BASIC_SCIENCE

Brief summary: Investigation of Glucose-dependent Insulinotropic Polypeptide (GIP) effects at hyper and hypoglycemia in type 1 diabetes.


Eligibility criteria: Inclusion Criteria:

• Diagnosed with type 1 diabetes (WHO criteria)

Exclusion Criteria:

* HbA1c \> 9 %
* Liver disease (ALAT/ASAT \> 2 x upper normal limit)
* Diabetic nephropathy (s-creatinine \> 130 µM or albuminuria)
* Proliferative diabetic retinopathy (anamnestic)
* Severe arteriosclerosis or heart failure (NYHA group III or IV)
* Anemia
* treatment with medication not applicable to pause for 12 hours
* C-peptide increase after 50 g iv arginine

Primary outcomes:
measure: plasma glucagon area under curve values
timeFrame: approx. 15 minutes intervals, time 0 to 120 min
Secondary outcomes:
measure: plasma gut hormones and nutrients (absolute, incremental and area under curve values)
timeFrame: approx. 15 minutes intervals, time 0 to 120 min
Other outcomes:
measure: Glucose and glycerol tracer kinetics
timeFrame: approx. 15 minutes intervals, time 0 to 120 min
measure: glucose (g/kg body weight) needed to be infuse to keep clamp
timeFrame: approx. 15 minutes intervals, time 0 to 120 min
Locations:
city: Hellerup
country: Denmark
facility: Gentofte Hospital
Study officials:
affiliation: Copenhagen University Hospital, Gentofte
name: Mikkel Christensen, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Christensen M, Calanna S, Sparre-Ulrich AH, Kristensen PL, Rosenkilde MM, Faber J, Purrello F, van Hall G, Holst JJ, Vilsboll T, Knop FK. Glucose-dependent insulinotropic polypeptide augments glucagon responses to hypoglycemia in type 1 diabetes. Diabetes. 2015 Jan;64(1):72-8. doi: 10.2337/db14-0440. Epub 2014 Jul 22.
Clinical trial NCT06969183: A Descriptive Exploration of Flourishing Through Kink
Official title: A Descriptive Exploration of Flourishing Through Kink
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Impact on Psychological Well-being of Involvement in Kink Behaviors
Keywords: kink, BDSM, flourishing, trauma recovery
Lead sponsor: The Alternative Sexualities Health Research Alliance
Sponsor class: OTHER
First posted: 2025-05-13
Enrollment: 1131
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: ECOLOGIC_OR_COMMUNITY
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: People who have engaged in kink behaviors

Brief summary: The study examines the experiences of people who have engaged in alternative sexual behaviors, like kink or BDSM, and whether there have been any positive effects on well-being

Detailed description: The study design is an observational, cross-sectional mixed methods study with data collected anonymously online via a computer-assisted survey through Qualtrics. Subjects will be recruited through nonprobability snowball sampling

Eligibility criteria: Inclusion Criteria:

- 1. Age of majority in the legal jurisdiction (geographic location) where the survey is taken (usually age 18) 2. Self-reported involvement in kink behaviors 3. self-reported English-language proficiency sufficient to understand the study instrument.

4. Answer correctly a series of questions to screen for bots and fraudulent responses

Exclusion Criteria:

* 1. Report no involvement in kink activities or behaviors 2. Answer incorrectly three or more questions for bot detection and fraudulent responses, 3+ out of 4 bot detection questions.

  3. Clearly fraudulent use of the internet survey, such as: evidence of non-human data entry via an internet "bot", duplicative or prank data entry that entails contradictory or clearly fraudulent data.

  4. Any condition that, in the professional judgment of the Principal Investigator, should exclude an individual from participation in the study.

Primary outcomes:
measure: Reports of Healing through Kink
timeFrame: Baseline
Secondary outcomes:
measure: Subgroups More Likely
timeFrame: Baseline
measure: Types of Trauma Involved
timeFrame: Baseline
measure: Attachment Differences
timeFrame: Baseline
measure: Healing and Flourishing
timeFrame: Baseline
measure: Conditions for Healing through Kink
timeFrame: Baseline
measure: AEDP Features of Healing through Kink
timeFrame: Baseline
measure: Level of current symptoms of Trauma
timeFrame: Baseline
measure: Flourishing
timeFrame: Baseline
Other outcomes:
Locations:
city: San Francisco
country: United States
facility: TASHRA
state: California
Study officials:
affiliation: The Alternative Sexualities Health Research Alliance
name: Richard A Sprott, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02880761: Cohort Study on A Following-up System of Native Arteriovenous Fistulae
Official title: Cohort Study on A Following-up System of Native Arteriovenous Fistulae in Chinese Patients Treated by Maintenance Hemodialysis
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Arteriovenous Fistulae
Keywords: hemodialysis
chronic renal failure
arteriovenous fistulae
Lead sponsor: Capital Medical University
Sponsor class: OTHER
Collaborators: name: Peking University International Hospital
First posted: 2016-08-26
Enrollment: 209
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: A cohort including more than 100 maintenance hemodialysis patients will be followed up according to a certain Following-up System of Native Arteriovenous Fistulae (AVF) prospectively. The assessment results of the Following-up System of AVF help the physicians make decisions of AVF surgery and puncture methods. The results of this study would identify the effect of the system on survival of AVF. Other 100 hemodialysis patients from other centers will be treated by routine protocol and compared to the experiment goup.

Detailed description: The Following-up System of AVF includes 3 stages. In the 1st stage, before AVF surgery operation, the contents of Following-up System of AVF include history, physical exam, ultrasonography detection. The assesment results will guide the methods of the AVF surgery operation. In the 2nd stage, before AVF puncture firstly and 3 months after AVF operation, the contents of Following-up System of AVF include physical exam and ultrasonography detection. The results will help the nurses and doctors make a decision of the method of AVF puncture. In the 3rd stage, during the following 2 years after AVF puncture successfully, the contents include physical exam and ultrasonography detection regularly. The adequacy of hemodialysis by using AVF will be assessed by urea clearance index (Kt/V).

The data of patients in other hemodialysis centers will be recorded and compared to the patients in experiment group.

Eligibility criteria: Inclusion Criteria:

* Maintenance hemodialysis patients using AVF;
* Ages 18-70 years old;
* Agreement with frequent following-up.

Exclusion Criteria:

* Younger than 18 years or elder than 70 years;
* Cachexia;
* Acute renal failure;
* Exceptive life time less than 6 months;
* Pregnant or planning pregnant;
* Waiting for renal transplantation or transferring to peritoneal dialysis.

Primary outcomes:
measure: Number of Participants With Fistula Failure
timeFrame: 3 months after surgery
Secondary outcomes:
measure: Life Time of AVF
timeFrame: Equal to or larger than 2 years
Other outcomes:
measure: Mean Value of Urea Clearance Index During 24 Months
timeFrame: 2 years
Locations:
city: Beijing
country: China
facility: Peking University International Hospital
state: Beijing
Study officials:
affiliation: Peking University Hospital
name: Dongliang Zhang, Doctor
role: STUDY_CHAIR
References:
Clinical trial NCT00170261: ELIAS: Early Loop-Recorder in Suspected Arrhythmogenic Syncope
Official title: Early Loop-Recorder in Suspected Arrhythmogenic Syncope
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Syncope
Keywords: Syncope of uncertain etiology
Repeated presyncopes
Lead sponsor: Medtronic Cardiac Rhythm and Heart Failure
Sponsor class: INDUSTRY
Collaborators: name: Medtronic
First posted: 2005-09-15
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: DIAGNOSTIC

Brief summary: This is a prospective, controlled, opened randomized study to evaluate the cost benefit of a primary implantation of a loop recorder versus the conventional diagnostic cascade for syncope most likely due to cardiac arrhythmia.


Eligibility criteria: Inclusion Criteria:

* Two or more episodes of syncope (most likely due to cardiac arrhythmia) of uncertain etiology within the last 12 months or more than one syncope and two presyncopes

Exclusion Criteria:

* Indication for the implantation of a pacemaker
* Indication for the implantation of an implantable cardioverter defibrillator
* Cardiac diseases which need intervention (KHK, aortic stenosis, mitral stenosis, left ventricular \[LV\] outflow stenosis, decompensated heart failure)
* Contraindication for a diagnostic procedure requested by the study protocol
* Enrollment in another study
* Circumstances or comorbidities which do not allow enrollment

Primary outcomes:
measure: Cost of diagnostics per patient until final cardiac diagnosis has been made
Secondary outcomes:
measure: Cost of diagnostics until final diagnosis has been made
measure: Rate of correct cardiac diagnoses
measure: Comparison of time needed to make a diagnosis
measure: Comparison of pre-syncopes and syncopes occuring in both groups after enrollment
Other outcomes:
Locations:
city: Berlin
country: Germany
facility: Vivantes Klinikum am Urban
city: Berlin
country: Germany
facility: Humbold Klinikum
city: Hamburg
country: Germany
facility: Universitätsklinikum Hamburg Eppendorf
Study officials:
affiliation: Vivantes Klinikum am Urban
name: H.-C- Ehlers, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01758861: Effect of Erythropoietin on the Incidence of Acute Kidney Injury Following Complex Valvular Heart Surgery
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Acute Kidney Injury
Keywords: Erythropoietin
acute kidney injury
valvular heart surgery
Lead sponsor: Yonsei University
Sponsor class: OTHER
First posted: 2013-01-01
Enrollment: 98
Sex: ALL
Minimum age (years): 20
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: Acute kidney injury (AKI) frequently occurs after cardiac surgery using cardiopulmonary bypass (CPB). Recombinant human erythropoietin (rHuEPO) is known to provide organ protection against ischemia-reperfusion injury through its anti-inflammatory properties. The aim of the present study was to investigate the effect of a single preoperative bolus of EPO on the incidence of AKI following complex valvular heart surgery in a randomized, controlled and double-blind trial.


Eligibility criteria: Inclusion Criteria:

* preoperative risk factors for AKI and scheduled for complex valvular heart operations
* Enrolled criteria for high risk of AKI were patients with more than 2 of bellows: female, serum creatinine \>1.2 mg/dl, preoperative A-fib, GFR \< 60 ml/min, NYHA class IV, HTN, DM, age \> 65 years, peripheral vascular disease.
* Complex valvular heart operations were defined as double-valve surgery, combined valve and coronary artery bypass grafting procedures, Bentall operation, combined mitral valve surgery and tricuspid annuloplasty or reoperation.

Exclusion Criteria:

* Patients with preexisting uncontrolled hypertension (diastolic blood pressure \> 100 mmHg), immunosuppression, history of thromboembolism, malignant disease, seizure, liver dysfunction, renal impairment (serum creatinine \> 2 mg/dL), and drug or alcohol abuse were excluded.

Primary outcomes:
measure: incidence of acute kidney injury
timeFrame: change of renal function including SCr, cystatin C, creatinine clearance from 24 h before operation to postoperative day (POD) 5
Secondary outcomes:
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Department of anesthesiology and pain medicine Yonsei University College of Medicine
Study officials:
References:
citation: Kim JH, Shim JK, Song JW, Song Y, Kim HB, Kwak YL. Effect of erythropoietin on the incidence of acute kidney injury following complex valvular heart surgery: a double blind, randomized clinical trial of efficacy and safety. Crit Care. 2013 Oct 24;17(5):R254. doi: 10.1186/cc13081.
Clinical trial NCT00004661: Study of the Regulation of Parathyroid Hormone Secretion in Pseudohypoparathyroidism
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Pseudohypoparathyroidism
Keywords: endocrine disorders
pseudohypoparathyroidism
rare disease
Lead sponsor: Office of Rare Diseases (ORD)
Sponsor class: NIH
Collaborators: name: University of California, Los Angeles
First posted: 2000-02-25
Enrollment: 20
Sex: ALL
Minimum age (years): 12
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no

Brief summary: OBJECTIVES:

Determine the relationship between serum calcium concentrations and parathyroid hormone secretion in patients with pseudohypoparathyroidism.

Detailed description: PROTOCOL OUTLINE:

Patients are tested for parathyroid hormone response following sequential graded intravenous infusions of sodium citrate and calcium gluconate. Assays include ionized calcium and intact parathyroid hormone.

Eligibility criteria: PROTOCOL ENTRY CRITERIA:

--Disease Characteristics-- Pseudohypoparathyroidism, i.e.: Renal resistance to parathyroid hormone OR Albright hereditary osteodystrophy No other illness unless related to pseudohypoparathyroidism No pregnant women

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: University of California, Los Angeles
name: Mitchell E. Geffner
role: STUDY_CHAIR
References: